Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

NCT04181788 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

155

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies
Non-small-cell Lung Cancer

Interventions

DRUG: PF-06801591

Sponsor

Pfizer